(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 6.34% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.47%.
Novartis Ag's revenue in 2019 is $48,677,000,000.On average, 2 Wall Street analysts forecast NVS's revenue for 2021 to be $123,861,420,141,111, with the lowest NVS revenue forecast at $122,843,314,459,065, and the highest NVS revenue forecast at $124,879,525,823,157. On average, 2 Wall Street analysts forecast NVS's revenue for 2022 to be $129,063,578,131,361, with the lowest NVS revenue forecast at $126,658,480,695,487, and the highest NVS revenue forecast at $131,468,675,567,236.
In 2023, NVS is forecast to generate $135,702,741,625,164 in revenue, with the lowest revenue forecast at $135,702,741,625,164 and the highest revenue forecast at $135,702,741,625,164.